Patricia Industries, backed by the industrial holding power of Investor AB, has finalized the acquisition of Advanced Instruments from Windjammer Capital. The strategic rationale for this transaction centers on a "resilience-driven" play, merging the target's undisputed leadership in the specialized osmolality testing market with the acquirer's long-term capital and healthcare sector expertise. This fusion effectively secures a high-margin, capital-light platform that benefits from non-discretionary demand across clinical and biopharmaceutical end markets. This operation allows the organization to execute a definitive structural expansion into the high-growth cell and gene therapy sectors, where the target's instrumentation is a mission-critical component of complex biologics production. By incorporating the target's innovative technology and deep customer relationships into its global industrial network, the organization can now provide more robust and integrated solutions for pharmaceutical quality control. The maneuver optimizes the group's portfolio by adding a business characterized by high recurring revenue and strong cash conversion. Ultimately, the partnership solidifies the group's standing as a primary enabler of analytical precision, bridging the gap between clinical diagnostic excellence and industrialized biopharmaceutical manufacturing standards.

ADVANCED INSTRUMENTS, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 12.8x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.